NEW YORK (AP) – Teva Pharmaceutical Industries Ltd. said the Food and Drug Administration approved its generic version of the heartburn drug Prevacid.
Teva will sell 15-milligram and 30-milligram delayed-release capsule versions of the drug.
Teva said the branded version of Prevacid had sales of about $2.97 billion in the 12 months ended June 30.
Date: November 10, 2009
Source: Associated Press
Filed Under: Drug Discovery
